Lipoprotein(a) as a Marker of Cardiovascular Health Risk: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Simonetta Genovesi
,
Marco Giussani
,
Giulia Lieti
,
Antonina Orlando
,
Ilenia Patti
,
Gianfranco Parati

Lipoprotein(a) [Lp(a)] is made up of apoprotein(a) [apo(a)] and LDL-like particle. The proportion of Lp(a) in each individual is genetically determined and is only minimally modifiable by environment or diet. Lp(a) has important pro-atherosclerotic and pro-inflammatory effects. For these reasons, high Lp(a) values are an important independent risk factor for cardiovascular disease and calcific aortic valve stenosis. Numerous studies have been performed in adults about the pathophysiology and epidemiology of Lp(a), much less information is available regarding Lp(a) in children and adolescents. Gaining information on these points is particularly important for deciding whether Lp(a) assay may be useful for defining the cardiovascular risk in children, in order to plan a prevention program early.

  • lipoprotein(a)
  • adolescents
  • cardiovascular risk

1. Introduction

Lipoprotein(a) (Lp(a)) was first described by K. Berg in 1963 [1]. For several years, interest in this lipoprotein was modest, until the sequencing of the LPA gene encoding apolipoprotein(a) (apo(a)), a key constituent of Lp(a) [2], and the subsequent recognition of Lp(a) as an independent risk factor for cardiovascular disease by epidemiological and Mendelian randomization studies [3][4]. Later, high Lp(a) values were also associated with calcific aortic valve stenosis [5] and increased risk of ischemic stroke [6][7].

2. Structure and Features of Lp(a)

Lp(a) consists of a very low-density lipoprotein (LDL)-like particle with apoprotein B100 being bound via a single disulfide link to a single apoprotein(a) (apo(a)) (Figure 1).
Biomedicines 11 01661 g001
Figure 1. Structure of lipoprotein(a). Lipoprotein(a) consists of a very low-density lipoprotein (LDL)-like particle, with apoprotein B100 (apo-B100) being bound via a single disulfide link to a single apoprotein a (apo(a)).
Apo(a) is a glycoprotein that has structural similarities with plasminogen. Plasminogen is made from a protein chain with a terminal part with protease activity joined to five aggregates of about 90 amino acids that have been named kringles because of their shape resembling that of a typical Northern European cake. In plasminogen, the kringles are present in single copy and are named with Roman numerals from KI to KV. Unlike plasminogen, apo(a) has an inactive protease domain and does not contain KI, KII, or KIII kringles, but consists of only one KV subtype and ten KIV subtypes, which are present in single copy except for the KIV2 subtype that can repeat from one to forty times [8] (Figure 2). Polypeptide structures similar to kringle domains are found in several enzymes (thrombin, tissue plasminogen activator, hepatocyte growth factor) as well as in plasminogen and Lp(a). The KVs of plasminogen and apo(a) have strong structural homology, as do the KIVs of plasminogen and Lp(a). However, KV and KIV are quite different from each other, both structurally and as amino acid composition. In contrast, the various subtypes 1 to 10 of KIV have important structural homologies and differ in their composition by only a few amino acids. These small differences may, however, account for different activities such as, for example, the ability to create disulfide bonds between KIV9 and apoB100. The specific function of KIV2 is not known, nor is the physiological function of Lp(a). The characteristic of KIV2 is its ability to be replicated a highly variable number of times in the structure of apo(a) [9].
Biomedicines 11 01661 g002
Figure 2. Schematic depiction of plasminogen and apoprotein (a). Apoprotein(a) is a glycoprotein with remarkable similarities to plasminogen, in both the protease part (P) and the inactive part (Pi), and in the kringle protein structure (K). The apoprotein(a) does not have KI to KIII, while it has KIV to KV; KV and subtypes 1 and 3 to 10 are expressed in single copy, while subtype 2 is pre-sent in variable copy numbers. Apoprotein(a) can vary greatly in length and molecular weight. Sialic acid (SA) with other N-glucans and O-glucans has structural functions and protects apoprotein(a) from proteases. Apoprotein(a) transports a considerable amount of oxidized phospholipids (flox), which, added to the LDL-like ones connected to apoprotein(a) via apoprotein B100 (ApoB100), make lipoprotein(a) the major carrier of oxidized phospholipids.
Thus, the length of apo(a) is highly variable and its molecular weight has a range from 275 to 800 kDa. Apo(a) contains a fair amount of oligosaccharides, in particular, sialic acid and other N-glycans and O-glycans, which have structural and protective functions against the activity of proteolytic enzymes [10][11]. Another relevant aspect in the structure of apo(a) is the presence of oxidized phospholipids, mainly attached to the KIV10 subtype. Considering also the proportion contained in the LDL-like component, Lp(a) is the major carrier of oxidized phospholipids [12], so individuals with high Lp(a) values are at greater risk of coronary heart disease and stroke. Apo(a) is produced exclusively by the endoplasmic reticulum of the liver, where it also undergoes post-translational modifications with the creation of a disulfide bond in each kringle that assumes the characteristic shape. The formation process is completed in the Golgi apparatus where the lipoprotein undergoes glycosylation [13]. The question of whether the assembly of Lp(a) with apo(a) and apoprotein B-100 takes place in the hepatocyte, on the surface or even outside, is not settled yet. Some studies suggest that an initial non-covalent bond between apo(a) and apoprotein B100 could be formed inside the hepatocyte [10], while the final disulfide bond that completes the formation of Lp(a) would be created outside the hepatocyte, in the Disse spaces of the hepatic sinusoids [14][15]. A small proportion of apo(a) remains unaggregated and is eliminated with urine; no particular function has been attributed to it [16]. The amount of circulating Lp(a) depends on how much apo(a) is produced by the liver, which, in turn, depends on the activity of the LPA gene, which, being made up of two codominant alleles, encodes two isoforms of apo(a) that may differ in length. In each individual, therefore, there are two different Lp(a)s which may have different molecular weights. The variability in Lp(a) levels in the general population is extremely high, and its plasma concentration can range from 0.1 to 300 mg/dL. Hepatic production of Lp(a) is 80–90% genetically determined; therefore, it is little affected by environmental factors and tends to be stable in adults [17]. Therefore, in this age group, a single Lp(a) assay may be sufficient to know the related risk profile of the individual. However, this point is a matter of debate, as it is reported that Lp(a) levels would change over time [18]; moreover, this occurs in the presence of certain diseases. First, it should be noted that Lp(a) behaves as an acute phase protein, so it tends to increase in inflammatory states [19] and this should be taken into account when scheduling the measurement. In addition, nephropathies are also associated with significant increases in Lp(a) levels, which can be explained by different mechanisms depending on the type of kidney disease. Already in the early stages of renal failure, an increase in Lp(a) can be shown, with increases proportional to the decrease in glomerular filtrate. However, in the nephrotic syndrome, Lp(a) can increase up to fourfold due to an increment of its synthesis by the liver [20]. Chronic kidney disease patients have a significantly increased risk of cardiovascular disease, related to the level of Lp(a) [21]. The amount of circulating Lp(a) is inversely proportional to the length of the apo(a), thus to the number of KIV2 kringles. Therefore, individuals with longer apo(a) isoforms of Lp(a), thus with higher molecular weight, produce less Lp(a) than those with shorter, lower molecular weight isoforms. The lower amount of Lp(a) produced by individuals in which the higher molecular weight isoforms predominate could be due to the longer time required for its production [22] or to the greater molecular weight isoforms that have not assumed the correct conformation being translocated outside the endoplasmic reticulum, ubiquitinated and degraded [23]. In addition to length, other genetic factors may influence the increased or decreased production of Lp(a). In particular, several single nucleotide polymorphisms of the LPA gene are known to be associated with increased or decreased apo(a) and Lp(a) production [24][25]. Regarding cardiovascular risk, it is currently believed that it would be related to the amount of circulating Lp(a) and not to its qualitative characteristics. Thus, subjects with higher plasma concentrations of this lipoprotein, who are those with lower molecular weight isoforms of Lp(a), are most at risk [3]. Lp(a) is metabolized mainly by the liver and to a lesser extent by the kidney. Several receptors are called upon for Lp(a) uptake, such as the BI scavenger receptor, plasminogen receptors, and LDL receptors, but these aspects are not yet fully elucidated [26]. The variability of Lp(a) gives reason for the difficulties there are in developing precise laboratory methods for its assay. In particular, when polyclonal antibodies, also directed toward the repeated part of apo(a) (KIV2), are used, larger isoforms tend to be overestimated, while smaller ones may be underestimated [27]. These difficulties can be overcome by performing analyses with calibrators containing Lp(a) of different lengths or with monoclonal antibodies directed only toward the single-copy portion of apo(a). Lp(a) assays are often expressed in mg/dL, as if directly measuring the entire lipoprotein, and thus, not only its protein part but also its cholesterol content, cholesterol esters, phospholipids, triglycerides, and carbohydrates. This is not quite correct because the assays reflect the quantitative molar ratio between apo(a) and the antibodies that interact with it. Therefore, it would be more correct to express Lp(a) values in nmol/L [27]. Again because of the variability of Lp(a), there can be no precise conversion factor between mg/dL and nmol/L. However, from a practical point of view, a conversion factor between 2 and 2.5 is still accepted [28].

3. Lp(a) and Cardiovascular Risk

Lp(a) is associated with an increased risk of cardiovascular events because of some of its structural and functional characteristics that promote atherosclerotic plaque formation and growth. In addition, it has been suggested that Lp(a) promotes coagulation processes following plaque rupture. This, however, is currently only a hypothesis and needs validation. Lp(a) contains a proportion of cholesterol that corresponds to about 30–40% of its weight [29]. This amount of cholesterol is less than that found in LDL and is negligible when circulating Lp(a) is in low concentration. However, in individuals who have high Lp(a) values, its contribution to the amount of atherogenic cholesterol can be significant, mainly due to the ease with which Lp(a) crosses the endothelium and accumulates in the inner layer of the artery wall, where it is able to activate smooth muscle cell proliferation and migration and foam cell formation [13]. Interestingly, high levels of Lp(a) promote the earlier stages of atherosclerosis and not just the more advanced phases. Imaging studies have shown that Lp(a) promotes the development of arterial wall inflammation [30] and that in the presence of coronary artery disease, high Lp(a) levels are associated with an increase in the amount of calcium and necrotic core volume from the atherosclerotic plaque [31][32]. The processes promoting inflammation and calcium deposition seem mainly related to the presence of oxidized phospholipids [33][34], which would be responsible for the secretion of chemotactic substances and proinflammatory cytokines, upregulation of adhesion molecules, and trans-endothelial migration of monocytes [30][35]. Finally, the presence in apo(a) of a protease-like domain similar to that of plasminogen, but inactive, suggests that Lp(a) might also have a role in promoting coagulation processes and reducing fibrinolysis. The latter effect of Lp(a) is still under debate [36]. However, it seems that Lp(a) has no role in venous thromboembolism events [37]. In summary, Lp(a) would have pro-atherosclerotic, pro-inflammatory, and possibly pro-coagulant and antifibrinolytic effects. Regarding calcific aortic valve stenosis, numerous studies have shown micro- and macro-calcifications of the aortic valve in adults aged 45 to 55 years with elevated Lp(a) values [5][38][39]. It is estimated that individuals with higher Lp(a) percentiles are three times more likely to develop calcific aortic valve stenosis than those with lower Lp(a) percentiles [38]. Furthermore, high plasma Lp(a) levels correlate with more rapid progression of valve stenosis [12]. The etiopathogenetic mechanisms explaining the association between Lp(a) and calcific aortic valve stenosis have yet to be elucidated; however, oxidized phospholipids would again be called into play, which, in addition to activating inflammatory processes, would stimulate the activation of genes that regulate osteoblastic processes in the cells of the valve interstitium [12][35].
Some considerations should be added regarding the relationship between hypolipidemic drug therapy and the levels of Lp(a). Statins have been reported to be associated with a tendency to increase Lp(a) levels, whereas ezetimibe would have no effect [40][41].
In contrast, apheresis [42] and drugs such as niacin [43] and PCSK9 inhibitors [44] are able to reduce plasma Lp(a) concentrations. However, while it has been shown that the decrease in Lp(a) levels induced by apheresis is approximately 75% and is associated, in subjects with extremely high Lp(a) levels, with a significant reduction in cardiovascular risk [42], the same clinical outcome is not achieved with the administration of niacin or PCSK9 inhibitors [45][46], which induce reductions in Lp(a) values of 20–30% [43][44]. On the basis of the current data, a significant reduction in cardiovascular risk by lowering Lp(a) awaits further studies. Of note, niacin and PCSK9 inhibitors do not currently have a pediatric indication.

4. Lp(a) in Adults

The plasma concentration of Lp(a) is widely variable, and in all populations, there are individuals with very-high Lp(a) values. However, important differences can be found in the distribution of Lp(a) in different ethnic groups. In fact, average Lp(a) values increase from Chinese, to South Asians, to Whites to Blacks, with average concentrations of 16, 19, 31, and 75 nmol/L, respectively [47]. Hispanics have values intermediate between South Asians and Caucasian Whites [48]. In general then, Black individuals are those with higher Lp(a) values; in fact, the mean value of the plasma Lp(a) concentration among Blacks is in the fifth quintile of the White population distribution [49]. These differences among the different ethnic groups would be largely explained by the greater presence of isoforms with lower KIV2 kringle number in the Black, Caucasian, and Hispanic populations, respectively, although mutations in the LPA gene and other yet unknown factors would play a non-secondary role [50][51]. A recent large study confirms the inverse relationship between the distribution of Lp(a) values and its isoforms and the different distribution among different ethnic groups [52]. The study shows that Chinese and South Asian populations have the lowest average Lp(a) values and largest isoforms, while Africans and Arabs have the highest concentrations and smallest isoforms. Europeans, Latin Americans, and Southeast Asians rank in between for both parameters. The same study shows a correlation between the presence of Lp(a) values greater than 50 mg/dL with the risk of myocardial infarction with an odds ratio of 1.48 (95% CI: 1.32–1.67) in the entire population. The risk increased from Africans, to Arabs, Chinese, Europeans, Latin Americans to Southeast Asians who had the highest odds ratio [52]. This study suggests that ethnicity should also be taken into account when assessing the cardiovascular risk associated with Lp(a) levels, as similar Lp(a) values might be associated with different patterns of cardiovascular risk in different ethnicities. Lp(a) values could also differ according to gender. However, the reports on this issue are conflicting: some authors report that males have higher values than females [53], while for other authors, the opposite would be true [47]. In males, Lp(a) values would remain consistent throughout adult life [54], whereas in females, there would be an increase after menopause [55][56][57][58]. In adults, the correlation between Lp(a) levels and cardiovascular risk has a linear and continuous pattern. In general, individuals with Lp(a) values less than 30 mg/dL can be considered at low risk and those with values greater than 50 mg/dL at high risk. Concentrations between 30 and 50 mg/dL are considered borderline [27]. It should be emphasized, however, that in the assessment of an individual’s cardiovascular risk, Lp(a) values are only one aspect, albeit an important one, that must be considered in the totality of the other known risk factors. The most recent European guidelines suggest that Lp(a) should be measured at least once in a lifetime in adults and that this information should be included in the overall estimate of the risk of developing atherosclerotic-based disease [27].

This entry is adapted from the peer-reviewed paper 10.3390/biomedicines11061661

References

  1. Berg, K. A new serum type system in man—The lp system. Acta Pathol. Microbiol. Scand. 1963, 59, 369–382.
  2. McLean, J.W.; Tomlinson, J.E.; Kuang, W.J.; Eaton, D.L.; Chen, E.Y.; Fless, G.M.; Scanu, A.M.; Lawn, R.M. CDNA Sequence of Human Apolipoprotein(a) Is Homologous to Plasminogen. Nature 1987, 330, 132–137.
  3. Erqou, S.; Thompson, A.; Di Angelantonio, E.; Saleheen, D.; Kaptoge, S.; Marcovina, S.; Danesh, J. Apolipoprotein(a) Isoforms and the Risk of Vascular Disease: Systematic Review of 40 Studies Involving 58,000 Participants. J. Am. Coll. Cardiol. 2010, 55, 2160–2167.
  4. Kamstrup, P.R.; Tybjaerg-Hansen, A.; Steffensen, R.; Nordestgaard, B.G. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA 2009, 301, 2331–2339.
  5. Thanassoulis, G.; Campbell, C.Y.; Owens, D.S.; Smith, J.G.; Smith, A.V.; Peloso, G.M.; Kerr, K.F.; Pechlivanis, S.; Budoff, M.J.; Harris, T.B.; et al. Genetic Associations with Valvular Calcification and Aortic Stenosis. N. Engl. J. Med. 2013, 368, 503–512.
  6. Langsted, A.; Nordestgaard, B.G.; Kamstrup, P.R. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J. Am. Coll. Cardiol. 2019, 74, 54–66.
  7. Koschinsky, M.L.; Kronenberg, F. The Long Journey of Lipoprotein(a) from Cardiovascular Curiosity to Therapeutic Target. Atherosclerosis 2022, 349, 1–6.
  8. van der Hoek, Y.Y.; Wittekoek, M.E.; Beisiegel, U.; Kastelein, J.J.; Koschinsky, M.L. The Apolipoprotein(a) Kringle IV Repeats Which Differ from the Major Repeat Kringle Are Present in Variably-Sized Isoforms. Hum. Mol. Genet. 1993, 2, 361–366.
  9. Santonastaso, A.; Maggi, M.; De Jonge, H.; Scotti, C. High Resolution Structure of Human Apolipoprotein (a) Kringle IV Type 2: Beyond the Lysine Binding Site. J. Lipid Res. 2020, 61, 1687–1696.
  10. Garner, B.; Merry, A.H.; Royle, L.; Harvey, D.J.; Rudd, P.M.; Thillet, J. Structural Elucidation of the N- and O-Glycans of Human Apolipoprotein(a): Role of o-Glycans in Conferring Protease Resistance. J. Biol. Chem. 2001, 276, 22200–22208.
  11. Kostner, G.M. Lp(a) Biochemistry, Composition, and Structure. In Lipoprotein(a); Kostner, K., Kostner, G.M., Toth, P.P., Eds.; Contemporary Cardiology; Springer International Publishing: Cham, Switzerland, 2023; pp. 39–54. ISBN 978-3-031-24575-6.
  12. Zheng, K.H.; Tsimikas, S.; Pawade, T.; Kroon, J.; Jenkins, W.S.A.; Doris, M.K.; White, A.C.; Timmers, N.K.L.M.; Hjortnaes, J.; Rogers, M.A.; et al. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients with Aortic Stenosis. J. Am. Coll. Cardiol. 2019, 73, 2150–2162.
  13. Chemello, K.; Chan, D.C.; Lambert, G.; Watts, G.F. Recent Advances in Demystifying the Metabolism of Lipoprotein(a). Atherosclerosis 2022, 349, 82–91.
  14. Koschinsky, M.L.; Marcovina, S.M. Structure-Function Relationships in Apolipoprotein(a): Insights into Lipoprotein(a) Assembly and Pathogenicity. Curr. Opin. Lipidol. 2004, 15, 167–174.
  15. Becker, L.; Nesheim, M.E.; Koschinsky, M.L. Catalysis of Covalent Lp(a) Assembly: Evidence for an Extracellular Enzyme Activity That Enhances Disulfide Bond Formation. Biochemistry 2006, 45, 9919–9928.
  16. Mooser, V.; Marcovina, S.M.; White, A.L.; Hobbs, H.H. Kringle-Containing Fragments of Apolipoprotein(a) Circulate in Human Plasma and Are Excreted into the Urine. J. Clin. Investig. 1996, 98, 2414–2424.
  17. Borrelli, M.J.; Youssef, A.; Boffa, M.B.; Koschinsky, M.L. New Frontiers in Lp(a)-Targeted Therapies. Trends Pharmacol. Sci. 2019, 40, 212–225.
  18. Pagnan, A.; Kostner, G.; Braggion, M.; Ziron, L. Relationship between “sinking Pre-Beta-Lipoprotein” (Lp(a) Lipoprotein) and Age in a Family Kindred. Gerontology 1982, 28, 381–385.
  19. Reyes-Soffer, G.; Westerterp, M. Beyond Lipoprotein(a) Plasma Measurements: Lipoprotein(a) and Inflammation. Pharmacol. Res. 2021, 169, 105689.
  20. Kronenberg, F. Causes and Consequences of Lipoprotein(a) Abnormalities in Kidney Disease. Clin. Exp. Nephrol. 2014, 18, 234–237.
  21. Barbagelata, L.; Masson, W.; Corral, P.; Lavalle-Cobo, A.; Nogueira, J.P.; Rosa Diez, G. Relationship between Lipoprotein(a) Levels, Cardiovascular Outcomes and Death in Patients with Chronic Kidney Disease: A Systematic Review of Prospective Studies. J. Nephrol. 2023.
  22. Chan, D.C.; Watts, G.F.; Coll, B.; Wasserman, S.M.; Marcovina, S.M.; Barrett, P.H.R. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. J. Am. Heart Assoc. 2019, 8, e011781.
  23. Boffa, M.B.; Koschinsky, M.L. Understanding the Ins and Outs of Lipoprotein (a) Metabolism. Curr. Opin. Lipidol. 2022, 33, 185–192.
  24. Coassin, S.; Kronenberg, F. Lipoprotein(a) beyond the Kringle IV Repeat Polymorphism: The Complexity of Genetic Variation in the LPA Gene. Atherosclerosis 2022, 349, 17–35.
  25. Noureen, A.; Fresser, F.; Utermann, G.; Schmidt, K. Sequence Variation within the KIV-2 Copy Number Polymorphism of the Human LPA Gene in African, Asian, and European Populations. PLoS ONE 2015, 10, e0121582.
  26. McCormick, S.P.A.; Schneider, W.J. Lipoprotein(a) Catabolism: A Case of Multiple Receptors. Pathology 2019, 51, 155–164.
  27. Cegla, J.; France, M.; Marcovina, S.M.; Neely, R.D.G. Lp(a): When and How to Measure It. Ann. Clin. Biochem. 2021, 58, 16–21.
  28. Kronenberg, F. Lipoprotein(a) Measurement Issues: Are We Making a Mountain out of a Molehill? Atherosclerosis 2022, 349, 123–135.
  29. Kinpara, K.; Okada, H.; Yoneyama, A.; Okubo, M.; Murase, T. Lipoprotein(a)-Cholesterol: A Significant Component of Serum Cholesterol. Clin. Chim. Acta 2011, 412, 1783–1787.
  30. van der Valk, F.M.; Bekkering, S.; Kroon, J.; Yeang, C.; Van den Bossche, J.; van Buul, J.D.; Ravandi, A.; Nederveen, A.J.; Verberne, H.J.; Scipione, C.; et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation 2016, 134, 611–624.
  31. Garg, P.K.; Guan, W.; Karger, A.B.; Steffen, B.T.; Budoff, M.; Tsai, M.Y. Lipoprotein (a) and Risk for Calcification of the Coronary Arteries, Mitral Valve, and Thoracic Aorta: The Multi-Ethnic Study of Atherosclerosis. J. Cardiovasc. Comput. Tomogr. 2021, 15, 154–160.
  32. Kaiser, Y.; Daghem, M.; Tzolos, E.; Meah, M.N.; Doris, M.K.; Moss, A.J.; Kwiecinski, J.; Kroon, J.; Nurmohamed, N.S.; van der Harst, P.; et al. Association of Lipoprotein(a) With Atherosclerotic Plaque Progression. J. Am. Coll. Cardiol. 2022, 79, 223–233.
  33. Leibundgut, G.; Scipione, C.; Yin, H.; Schneider, M.; Boffa, M.B.; Green, S.; Yang, X.; Dennis, E.; Witztum, J.L.; Koschinsky, M.L.; et al. Determinants of Binding of Oxidized Phospholipids on Apolipoprotein (a) and Lipoprotein (a). J. Lipid Res. 2013, 54, 2815–2830.
  34. Koschinsky, M.L.; Boffa, M.B. Oxidized Phospholipid Modification of Lipoprotein(a): Epidemiology, Biochemistry and Pathophysiology. Atherosclerosis 2022, 349, 92–100.
  35. Dzobo, K.E.; Kraaijenhof, J.M.; Stroes, E.S.G.; Nurmohamed, N.S.; Kroon, J. Lipoprotein(a): An Underestimated Inflammatory Mastermind. Atherosclerosis 2022, 349, 101–109.
  36. Boffa, M.B.; Koschinsky, M.L. Lipoprotein (a): Truly a Direct Prothrombotic Factor in Cardiovascular Disease? J. Lipid Res. 2016, 57, 745–757.
  37. Nordestgaard, B.G.; Langsted, A. Lipoprotein (a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. J. Lipid Res. 2016, 57, 1953–1975.
  38. Kaiser, Y.; Singh, S.S.; Zheng, K.H.; Verbeek, R.; Kavousi, M.; Pinto, S.-J.; Vernooij, M.W.; Sijbrands, E.J.G.; Boekholdt, S.M.; de Rijke, Y.B.; et al. Lipoprotein(a) Is Robustly Associated with Aortic Valve Calcium. Heart 2021, 107, 1422–1428.
  39. Kaltoft, M.; Sigvardsen, P.E.; Afzal, S.; Langsted, A.; Fuchs, A.; Kühl, J.T.; Køber, L.; Kamstrup, P.R.; Kofoed, K.F.; Nordestgaard, B.G. Elevated Lipoprotein(a) in Mitral and Aortic Valve Calcification and Disease: The Copenhagen General Population Study. Atherosclerosis 2022, 349, 166–174.
  40. Tsimikas, S.; Gordts, P.L.S.M.; Nora, C.; Yeang, C.; Witztum, J.L. Statin Therapy Increases Lipoprotein(a) Levels. Eur. Heart J. 2020, 41, 2275–2284.
  41. Awad, K.; Mikhailidis, D.P.; Katsiki, N.; Muntner, P.; Banach, M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs 2018, 78, 453–462.
  42. Jaeger, B.R.; Richter, Y.; Nagel, D.; Heigl, F.; Vogt, A.; Roeseler, E.; Parhofer, K.; Ramlow, W.; Koch, M.; Utermann, G.; et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat. Clin. Pract. Cardiovasc. Med. 2009, 6, 229–239.
  43. AIM-HIGH Investigators; Boden, W.E.; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N. Engl. J. Med. 2011, 365, 2255–2267.
  44. O’Donoghue, M.L.; Fazio, S.; Giugliano, R.P.; Stroes, E.S.G.; Kanevsky, E.; Gouni-Berthold, I.; Im, K.; Lira Pineda, A.; Wasserman, S.M.; Češka, R.; et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 2019, 139, 1483–1492.
  45. Tsushima, T.; Tsushima, Y.; Sullivan, C.; Hatipoglu, B. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies. Endocr. Pract. 2022, S1530-891X(22)00901-6.
  46. Ibrahim, S.; Stroes, E.S.G. Therapy of Elevated Lipoprotein(a). In Lipoprotein(a); Kostner, K., Kostner, G.M., Toth, P.P., Eds.; Contemporary Cardiology; Springer International Publishing: Cham, Switzerland, 2023; pp. 347–357. ISBN 978-3-031-24575-6.
  47. Mehta, A.; Jain, V.; Saeed, A.; Saseen, J.J.; Gulati, M.; Ballantyne, C.M.; Virani, S.S. Lipoprotein(a) and Ethnicities. Atherosclerosis 2022, 349, 42–52.
  48. Patel, A.P.; Wang, M.; Pirruccello, J.P.; Ellinor, P.T.; Ng, K.; Kathiresan, S.; Khera, A.V. Lp(a) (Lipoprotein) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights from a Large National Biobank. Arterioscler. Thromb. Vasc. Biol. 2021, 41, 465–474.
  49. Virani, S.S.; Brautbar, A.; Davis, B.C.; Nambi, V.; Hoogeveen, R.C.; Sharrett, A.R.; Coresh, J.; Mosley, T.H.; Morrisett, J.D.; Catellier, D.J.; et al. Associations between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2012, 125, 241–249.
  50. Tsimikas, S.; Clopton, P.; Brilakis, E.S.; Marcovina, S.M.; Khera, A.; Miller, E.R.; de Lemos, J.A.; Witztum, J.L. Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors: Results from the Dallas Heart Study. Circulation 2009, 119, 1711–1719.
  51. Deo, R.C.; Wilson, J.G.; Xing, C.; Lawson, K.; Kao, W.H.L.; Reich, D.; Tandon, A.; Akylbekova, E.; Patterson, N.; Mosley, T.H.; et al. Single-Nucleotide Polymorphisms in LPA Explain Most of the Ancestry-Specific Variation in Lp(a) Levels in African Americans. PLoS ONE 2011, 6, e14581.
  52. Paré, G.; Çaku, A.; McQueen, M.; Anand, S.S.; Enas, E.; Clarke, R.; Boffa, M.B.; Koschinsky, M.; Wang, X.; Yusuf, S.; et al. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation 2019, 139, 1472–1482.
  53. Varvel, S.; McConnell, J.P.; Tsimikas, S. Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 2239–2245.
  54. Trinder, M.; Paruchuri, K.; Haidermota, S.; Bernardo, R.; Zekavat, S.M.; Gilliland, T.; Januzzi, J.; Natarajan, P. Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk. J. Am. Coll. Cardiol. 2022, 79, 617–628.
  55. Jenner, J.L.; Ordovas, J.M.; Lamon-Fava, S.; Schaefer, M.M.; Wilson, P.W.; Castelli, W.P.; Schaefer, E.J. Effects of Age, Sex, and Menopausal Status on Plasma Lipoprotein(a) Levels. The Framingham Offspring Study. Circulation 1993, 87, 1135–1141.
  56. Derby, C.A.; Crawford, S.L.; Pasternak, R.C.; Sowers, M.; Sternfeld, B.; Matthews, K.A. Lipid Changes during the Menopause Transition in Relation to Age and Weight: The Study of Women’s Health Across the Nation. Am. J. Epidemiol. 2009, 169, 1352–1361.
  57. Anagnostis, P.; Antza, C.; Trakatelli, C.; Lambrinoudaki, I.; Goulis, D.G.; Kotsis, V. The Effect of Menopause on Lipoprotein (a) Concentrations: A Systematic Review and Meta-Analysis. Maturitas 2023, 167, 39–45.
  58. Simony, S.B.; Mortensen, M.B.; Langsted, A.; Afzal, S.; Kamstrup, P.R.; Nordestgaard, B.G. Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study. Atherosclerosis 2022, 355, 76–82.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback